Table 1. Baseline patient characteristics.
| Items | Number or Percentage |
| Age (yrs) | 57 ± 15 |
| Males | 76.7% |
| LVEF | 33% ± 14% |
| Patients with LVEF < 35% | 76.7% |
| Patients with LVEF ≥ 45% | 16.2% |
| New York Heart Association class | |
| III or IV | 69.8% |
| I or II | 30.2% |
| Heart disease etiology | |
| Ischemic heart disease | 48.8% |
| Dilated cardiomyopathy | 39.6% |
| LQTS | 2.3% |
| ARVC | 2.3% |
| Idiopathic VT/VF | 7% |
| Implanted device | |
| CRT-D | 48.8% |
| ICD | 51.2% |
| SCD prevention | |
| Primary prevention | 60.5% |
| Secondary prevention | 39.5% |
| Medication | |
| Βeta blockers | 100% |
| ACEI/ARB | 83.7% |
| Digoxin | 72.1% |
| Diuretics | 86% |
| Aldosterone antagonist | 88.4% |
ACEI/ARB: angiotensin converting enzyme inhibitor/angiotensin receptor blocker; ARVC: arrhythmogenic right ventricular cardiomyopathy; CRT-D: cardiac resynchronization therapy-defibrillator; ICD: implantable cardioverter-defibrillator; LQTS: long QT syndrome; LVEF: left ventricular ejection fraction; SCD: sudden cardiac death; VT/VF: ventricular tachycardia/ventricular fibrillation.